Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study
NCT04842747 · View on ClinicalTrials.gov ↗
Study Summary
To demonstrate the efficacy of VERU-111 in the treatment of SARS-Cov-2 Infection by assessing its effect on the proportion of patients who die on study (prior to Day 60).
Conditions Studied
Interventions
- DRUG VERU-111
Study Locations (20)
New Jersey
- Inspira Medical Center Mullica Hill — Mullica Hill
- Holy Name Medical Center, Institute for Clinical Research — Teaneck
- Inspira Medical Center — Vineland
Tennessee
- The Stern Cardiovascular Foundation, Inc. — Germantown
- Regional One Health — Memphis
- North Knoxville Medical Center — Powell
California
- Velocity Clinical Research — Chula Vista
- Velocity Clinical Research - San Diego — La Mesa
Florida
- Westchester General Hospital, Research Department — Miami
- James A. Haley Veterans Hospital — Tampa
Minnesota
- Methodist Hospital — Saint Louis Park
- Regions Hospital — Saint Paul
North Carolina
- University of North Carolina — Chapel Hill
- Atrium Health Carolinas Medical Center — Charlotte
Texas
- HD Research (Memorial Hermann - Memorial City Medical Center) — Houston
- HD Research (Memorial Hermann Southeast Hospital) — Houston
Arizona
- Honor Health — Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 204 participants |
| Start Date | 2021-05-18 |
| Est. Completion | 2022-07-06 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04842747
The ClinicalTrials.gov registry entry for NCT04842747 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 204 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Veru, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with SARS-CoV Infection appearing as the primary indexed condition, and to 1 intervention — of which VERU-111 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04842747 reports 20 study locations spanning 11 distinct geographic areas — top geographies include New Jersey, Tennessee, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04842747 about?
NCT04842747 is a clinical study titled "VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study". To demonstrate the efficacy of VERU-111 in the treatment of SARS-Cov-2 Infection by assessing its effect on the proportion of patients who die on study (prior to Day 60).
What is the current status of trial NCT04842747?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 204 participants. The study started on 2021-05-18. Estimated completion is 2022-07-06.
What conditions does trial NCT04842747 study?
This clinical trial studies the following conditions: SARS-CoV Infection. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT04842747?
The interventions under investigation include: VERU-111 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT04842747?
This trial is sponsored by Veru, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04842747 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.